December 12th 2024
Swanson and Lockshin explored how PDE4 inhibitors improve quality of life for AD patients through targeted treatments that address both inflammation and chronic symptoms.
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis
View More
Expert Opinions on the Role of Corticosteroids in Dermatological Conditions
October 3rd 2023James Q Del Rosso, DO and TJ Chao, MPAS, PA-C discuss the role of topical agents in the management of dermatological conditions reviewing their position and role within the treatment landscape for dermatological conditions.
Clinician and Patient Pearls on Managing Atopic Dermatitis
September 27th 2023Jennifer Holman, MD, FAAD, and her patient, Audrey Dean, discuss pearls and key take-aways from their experience managing atopic dermatitis. Jennifer Holman wraps up discussing anticipated therapeutic developments and unmet needs.
Therapeutic Evolutions in the Treatment Landscape of Atopic Dermatitis
September 27th 2023Jennifer Holman, MD, FAAD, reflects on the improvements in therapeutic treatments and outcomes for patients like Audrey Dean, and how her experience and quality of life has also improved with these medical advances.
Patient and Doctor Discussion on Side Effects and Managing Treatment for Atopic Dermatitis
September 20th 2023Audrey Dean discusses her experience of atopic dermatitis therapeutic side effects with her dermatologist, Jennifer Holman, MD, FAAD. Jennifer Holman goes on to highlight key pearls on managing patients with atopic dermatitis.
A Patient’s Disease Severity Experience With Supportive Therapies and Dietary Changes
September 20th 2023Audrey Dean discusses with her dermatologist, Jennifer Holman, MD, FAAD, how supportive therapies and dietary changes have altered her disease severity. Jennifer Holman goes on to highlight a wholistic approach to treatment, and how treating atopic dermatitis can have a multidisciplinary approach.
Conclusions of JAK Inhibitor vs Systemic Immunosuppressant Safety Study
September 6th 2023Christopher Bunick, MD, PhD, presents the conclusions and major take-aways of the study comparing the safety of Janus Kinase (JAK) inhibitors and systemic immunosuppressants in the treatment of atopic dermatitis (AD).